Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience From a Single Institution

George R. Simon, John C. Ruckdeschel, Charles Williams, Alan Cantor, Alberto Chiappori, Caio M.Rocha Lima, Scott Antonia, Eric Haura, Henry Wagner Jr., Lary Robinson, Eric Sommers, Michael Alberts, Gerold Bepler

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8%, but an additional 53.5% of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35%. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35% in a cohort of patients who were able to take the drug for at least 12 weeks.

Original languageEnglish (US)
Pages (from-to)388-395
Number of pages8
JournalCancer Control
Volume10
Issue number5
DOIs
StatePublished - Jan 1 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Survival Rate
Survival
gefitinib
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Disease-Free Survival
Diarrhea
Histology
Adenocarcinoma
Carcinoma
Skin
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Simon, G. R., Ruckdeschel, J. C., Williams, C., Cantor, A., Chiappori, A., Lima, C. M. R., ... Bepler, G. (2003). Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience From a Single Institution. Cancer Control, 10(5), 388-395. https://doi.org/10.1177/107327480301000506
Simon, George R. ; Ruckdeschel, John C. ; Williams, Charles ; Cantor, Alan ; Chiappori, Alberto ; Lima, Caio M.Rocha ; Antonia, Scott ; Haura, Eric ; Wagner Jr., Henry ; Robinson, Lary ; Sommers, Eric ; Alberts, Michael ; Bepler, Gerold. / Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer : Experience From a Single Institution. In: Cancer Control. 2003 ; Vol. 10, No. 5. pp. 388-395.
@article{71c5d2fc255741a09951dc4bea29e1ef,
title = "Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience From a Single Institution",
abstract = "Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8{\%}, but an additional 53.5{\%} of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35{\%}. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35{\%} in a cohort of patients who were able to take the drug for at least 12 weeks.",
author = "Simon, {George R.} and Ruckdeschel, {John C.} and Charles Williams and Alan Cantor and Alberto Chiappori and Lima, {Caio M.Rocha} and Scott Antonia and Eric Haura and {Wagner Jr.}, Henry and Lary Robinson and Eric Sommers and Michael Alberts and Gerold Bepler",
year = "2003",
month = "1",
day = "1",
doi = "10.1177/107327480301000506",
language = "English (US)",
volume = "10",
pages = "388--395",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "5",

}

Simon, GR, Ruckdeschel, JC, Williams, C, Cantor, A, Chiappori, A, Lima, CMR, Antonia, S, Haura, E, Wagner Jr., H, Robinson, L, Sommers, E, Alberts, M & Bepler, G 2003, 'Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience From a Single Institution', Cancer Control, vol. 10, no. 5, pp. 388-395. https://doi.org/10.1177/107327480301000506

Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer : Experience From a Single Institution. / Simon, George R.; Ruckdeschel, John C.; Williams, Charles; Cantor, Alan; Chiappori, Alberto; Lima, Caio M.Rocha; Antonia, Scott; Haura, Eric; Wagner Jr., Henry; Robinson, Lary; Sommers, Eric; Alberts, Michael; Bepler, Gerold.

In: Cancer Control, Vol. 10, No. 5, 01.01.2003, p. 388-395.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer

T2 - Experience From a Single Institution

AU - Simon, George R.

AU - Ruckdeschel, John C.

AU - Williams, Charles

AU - Cantor, Alan

AU - Chiappori, Alberto

AU - Lima, Caio M.Rocha

AU - Antonia, Scott

AU - Haura, Eric

AU - Wagner Jr., Henry

AU - Robinson, Lary

AU - Sommers, Eric

AU - Alberts, Michael

AU - Bepler, Gerold

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8%, but an additional 53.5% of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35%. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35% in a cohort of patients who were able to take the drug for at least 12 weeks.

AB - Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8%, but an additional 53.5% of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35%. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35% in a cohort of patients who were able to take the drug for at least 12 weeks.

UR - http://www.scopus.com/inward/record.url?scp=10744229425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744229425&partnerID=8YFLogxK

U2 - 10.1177/107327480301000506

DO - 10.1177/107327480301000506

M3 - Review article

C2 - 14581894

AN - SCOPUS:10744229425

VL - 10

SP - 388

EP - 395

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 5

ER -